Arcus Biosciences, Inc. (NYSE:RCUS) Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC decreased its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS) by 5.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 27,094 shares of the company’s stock after selling 1,605 shares during the period. Yousif Capital Management LLC’s holdings in Arcus Biosciences were worth $517,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Arcus Biosciences by 20.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,732 shares of the company’s stock worth $246,000 after acquiring an additional 2,289 shares in the last quarter. BluePath Capital Management LLC acquired a new stake in shares of Arcus Biosciences in the third quarter worth $28,000. Strs Ohio acquired a new stake in shares of Arcus Biosciences in the third quarter worth $43,000. Panagora Asset Management Inc. increased its position in shares of Arcus Biosciences by 2.2% in the third quarter. Panagora Asset Management Inc. now owns 99,299 shares of the company’s stock worth $1,782,000 after acquiring an additional 2,107 shares in the last quarter. Finally, Teacher Retirement System of Texas increased its position in shares of Arcus Biosciences by 13.6% in the third quarter. Teacher Retirement System of Texas now owns 13,496 shares of the company’s stock worth $242,000 after acquiring an additional 1,613 shares in the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

Arcus Biosciences Trading Up 1.3 %

RCUS opened at $15.70 on Monday. The company has a fifty day simple moving average of $17.25 and a 200 day simple moving average of $16.59. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -3.78 and a beta of 0.91. Arcus Biosciences, Inc. has a twelve month low of $12.95 and a twelve month high of $25.47.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings data on Wednesday, February 21st. The company reported ($1.08) EPS for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.01. Arcus Biosciences had a negative net margin of 262.39% and a negative return on equity of 57.17%. The firm had revenue of $31.00 million for the quarter, compared to the consensus estimate of $28.30 million. During the same period in the prior year, the firm posted ($0.93) EPS. The firm’s revenue was down 8.8% compared to the same quarter last year. On average, analysts forecast that Arcus Biosciences, Inc. will post -3.59 earnings per share for the current fiscal year.

Insider Buying and Selling at Arcus Biosciences

In other Arcus Biosciences news, President Juan C. Jaen sold 3,900 shares of the stock in a transaction on Monday, February 26th. The shares were sold at an average price of $20.06, for a total transaction of $78,234.00. Following the transaction, the president now directly owns 1,211,365 shares in the company, valued at approximately $24,299,981.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Arcus Biosciences news, President Juan C. Jaen sold 3,900 shares of the stock in a transaction on Monday, February 26th. The shares were sold at an average price of $20.06, for a total transaction of $78,234.00. Following the transaction, the president now directly owns 1,211,365 shares in the company, valued at approximately $24,299,981.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Jennifer Jarrett sold 24,555 shares of the stock in a transaction on Monday, February 26th. The shares were sold at an average price of $20.07, for a total transaction of $492,818.85. Following the transaction, the chief operating officer now owns 274,323 shares in the company, valued at $5,505,662.61. The disclosure for this sale can be found here. Insiders have sold 53,455 shares of company stock worth $1,014,779 in the last ninety days. 13.80% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Truist Financial reissued a “buy” rating and issued a $50.00 price objective on shares of Arcus Biosciences in a research report on Monday, March 25th. Wedbush reaffirmed an “outperform” rating and set a $30.00 price target on shares of Arcus Biosciences in a report on Thursday, February 22nd. Finally, Mizuho lowered their price target on shares of Arcus Biosciences from $51.00 to $42.00 and set a “buy” rating for the company in a report on Tuesday, January 30th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $41.25.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.